Research programme: hepatitis C therapy - Pharmasset/Roche
Latest Information Update: 03 Mar 2008
Price :
$50 *
At a glance
- Originator Pharmasset
- Class Nucleosides
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hepatitis C